# WIKINGO Proyect Systematic Analysis

Tables & Figures.

Proyecto Vikingo September 29, 2016

proyectovikingo@proyectovikingo.es

# Contents

•	• ,	C	<b>CD</b> 1	
П.	1St.	Ωt	Tah	IPS

1	Participant characteristics	:
2	According to Local Recurrence	
3	According to Metastasis	
4	According to Exitus	
5	Incidence by outcome [95% CI]	
List	of Figures	
$\mathbf{List}$		ŗ
$\mathbf{List}$	Local Recurrence	
1	Local Recurrence	7
$\begin{array}{c} 1 \\ 2 \end{array}$	Local Recurrence	9
1 2 3	Local Recurrence	7 9 10

Table 1: Participant characteristics

Age       65.9 (11.0)       552         Sex: Men       377 (68.3%)       552         Tumor level:       552         0-6cm       204 (37.0%)         7-12cm       285 (51.6%)         13-15cm       63 (11.4%)         Tumor stage:       552         0       54 (9.78%)         I       151 (27.4%)         II       169 (30.6%)         III       178 (32.2%)         Neoadjuvant treatment       381 (69.0%)       552         Type of resection:       552         Abdominoperineal resection       94 (17.0%)         Anterior resection       413 (74.8%)         Hartmann       45 (8.15%)         Perforation       22 (3.99%)       552         Invasion circumferential margin       45 (8.15%)       552         Mesorrecto quality:       552         Satisfactory       446 (80.8%)       7         Partial       63 (11.4%)       63 (11.4%)         No-satisfactory       43 (7.79%)       43 (7.79%)         Recidive       22 (3.99%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552 <td< th=""><th></th><th>[ATT]</th><th></th><th></th></td<>		[ATT]		
Age       65.9 (11.0)       552         Sex: Men       377 (68.3%)       552         Tumor level:       552         0-6cm       204 (37.0%)         7-12cm       285 (51.6%)         13-15cm       63 (11.4%)         Tumor stage:       552         0       54 (9.78%)         I       151 (27.4%)         II       169 (30.6%)         III       178 (32.2%)         Neoadjuvant treatment       381 (69.0%)       552         Type of resection:       552         Abdominoperineal resection       94 (17.0%)         Anterior resection       413 (74.8%)         Hartmann       45 (8.15%)         Perforation       22 (3.99%)       552         Invasion circumferential margin       45 (8.15%)       552         Mesorrecto quality:       552         Satisfactory       446 (80.8%)       446 (80.8%)         Partial       63 (11.4%)       63 (11.4%)         No-satisfactory       43 (7.79%)         Recidive       22 (3.99%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metas		[ALL] N-552		N
Sex: Men       377 (68.3%)       552         Tumor level:       552         0-6cm       204 (37.0%)         7-12cm       285 (51.6%)         13-15cm       63 (11.4%)         Tumor stage:       552         0       54 (9.78%)         I       151 (27.4%)         II       169 (30.6%)         III       178 (32.2%)         Neoadjuvant treatment       381 (69.0%)       552         Type of resection:       94 (17.0%)         Abdominoperineal resection       94 (17.0%)         Anterior resection       413 (74.8%)         Hartmann       45 (8.15%)         Perforation       22 (3.99%)       552         Invasion circumferential margin       45 (8.15%)       552         Mesorrecto quality:       552         Satisfactory       446 (80.8%)       446 (80.8%)         Partial       63 (11.4%)       63 (11.4%)         No-satisfactory       43 (7.79%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552 <td> A ma</td> <td>11-002</td> <td>65.0 (11.0)</td> <td>550</td>	 A ma	11-002	65.0 (11.0)	550
Tumor level:       552         0-6cm       204 (37.0%)         7-12cm       285 (51.6%)         13-15cm       63 (11.4%)         Tumor stage:       552         0       54 (9.78%)         I       151 (27.4%)         II       169 (30.6%)         III       178 (32.2%)         Neoadjuvant treatment       381 (69.0%)       552         Type of resection:       552         Abdominoperineal resection       94 (17.0%)         Anterior resection       413 (74.8%)         Hartmann       45 (8.15%)         Perforation       22 (3.99%)       552         Invasion circumferential margin       45 (8.15%)       552         Mesorrecto quality:       552         Satisfactory       446 (80.8%)       552         Partial       63 (11.4%)       63 (11.4%)         No-satisfactory       43 (7.79%)       8         Recidive       22 (3.99%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552 <td>_</td> <td></td> <td>` ′</td> <td></td>	_		` ′	
0-6cm       204 (37.0%)         7-12cm       285 (51.6%)         13-15cm       63 (11.4%)         Tumor stage:       552         0       54 (9.78%)         I       151 (27.4%)         II       169 (30.6%)         III       178 (32.2%)         Neoadjuvant treatment       381 (69.0%)       552         Type of resection:       552         Abdominoperineal resection       94 (17.0%)         Anterior resection       413 (74.8%)         Hartmann       45 (8.15%)         Perforation       22 (3.99%)       552         Invasion circumferential margin       45 (8.15%)       552         Mesorrecto quality:       552         Satisfactory       446 (80.8%)       552         Partial       63 (11.4%)       63 (11.4%)         No-satisfactory       43 (7.79%)         Recidive       22 (3.99%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552			377 (08.3%)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			004 (07 007)	552
Tumor stage: 552  0 54 (9.78%)  I 151 (27.4%)  II 169 (30.6%)  III 178 (32.2%)  Neoadjuvant treatment 381 (69.0%) 552  Type of resection: 552  Abdominoperineal resection 413 (74.8%)  Hartmann 45 (8.15%)  Perforation 22 (3.99%) 552  Invasion circumferential margin 45 (8.15%) 552  Mesorrecto quality: 552  Satisfactory 446 (80.8%)  Partial 63 (11.4%)  No-satisfactory 43 (7.79%)  Recidive 22 (3.99%) 552  Months to recidive 30.0 [5.00;60.0] 552  Metastasis 54 (9.78%) 552  Months to Metastasis 29.0 [5.00;57.2] 552  Exitus 68 (12.3%) 552			,	
Tumor stage:       552         0       54 (9.78%)         I       151 (27.4%)         III       169 (30.6%)         IIII       178 (32.2%)         Neoadjuvant treatment       381 (69.0%)       552         Type of resection:       552         Abdominoperineal resection       94 (17.0%)         Anterior resection       413 (74.8%)         Hartmann       45 (8.15%)         Perforation       22 (3.99%)       552         Invasion circumferential margin       45 (8.15%)       552         Mesorrecto quality:       552         Satisfactory       446 (80.8%)       552         Partial       63 (11.4%)       63 (11.4%)         No-satisfactory       43 (7.79%)       7.79%)         Recidive       22 (3.99%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552			,	
0       54 (9.78%)         I       151 (27.4%)         III       169 (30.6%)         III       178 (32.2%)         Neoadjuvant treatment       381 (69.0%)       552         Type of resection:       552         Abdominoperineal resection       94 (17.0%)         Anterior resection       413 (74.8%)         Hartmann       45 (8.15%)         Perforation       22 (3.99%)       552         Invasion circumferential margin       45 (8.15%)       552         Mesorrecto quality:       552         Satisfactory       446 (80.8%)       552         Partial       63 (11.4%)       63 (11.4%)         No-satisfactory       43 (7.79%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552			63 (11.4%)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Tumor stage:			552
III       169 (30.6%)         III       178 (32.2%)         Neoadjuvant treatment       381 (69.0%)       552         Type of resection:       552         Abdominoperineal resection       94 (17.0%)         Anterior resection       413 (74.8%)         Hartmann       45 (8.15%)         Perforation       22 (3.99%)       552         Invasion circumferential margin       45 (8.15%)       552         Mesorrecto quality:       552         Satisfactory       446 (80.8%)       446 (80.8%)         Partial       63 (11.4%)       63 (11.4%)         No-satisfactory       43 (7.79%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552	ŭ		` ,	
III       178 (32.2%)         Neoadjuvant treatment       381 (69.0%)       552         Type of resection:       552         Abdominoperineal resection       94 (17.0%)         Anterior resection       413 (74.8%)         Hartmann       45 (8.15%)         Perforation       22 (3.99%)       552         Invasion circumferential margin       45 (8.15%)       552         Mesorrecto quality:       552         Satisfactory       446 (80.8%)       446 (80.8%)         Partial       63 (11.4%)       63 (11.4%)         No-satisfactory       43 (7.79%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552			,	
Neoadjuvant treatment       381 (69.0%)       552         Type of resection:       552         Abdominoperineal resection       94 (17.0%)         Anterior resection       413 (74.8%)         Hartmann       45 (8.15%)         Perforation       22 (3.99%)       552         Invasion circumferential margin       45 (8.15%)       552         Mesorrecto quality:       552         Satisfactory       446 (80.8%)       552         Partial       63 (11.4%)       63 (11.4%)         No-satisfactory       43 (7.79%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552	II		169 (30.6%)	
Type of resection:       552         Abdominoperineal resection       94 (17.0%)         Anterior resection       413 (74.8%)         Hartmann       45 (8.15%)         Perforation       22 (3.99%)       552         Invasion circumferential margin       45 (8.15%)       552         Mesorrecto quality:       552         Satisfactory       446 (80.8%)       446 (80.8%)         Partial       63 (11.4%)       63 (11.4%)         No-satisfactory       43 (7.79%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552	III		178 (32.2%)	
Abdominoperineal resection Anterior resection Anterior resection Hartmann 45 (8.15%) Perforation 22 (3.99%) 552 Invasion circumferential margin Mesorrecto quality: 552 Satisfactory 446 (80.8%) Partial 63 (11.4%) No-satisfactory 43 (7.79%) Recidive 22 (3.99%) 552 Months to recidive 30.0 [5.00;60.0] 552 Metastasis 54 (9.78%) 552 Months to Metastasis 29.0 [5.00;57.2] 552 Exitus	Neoadjuvant treatment		381~(69.0%)	552
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Type of resection:			552
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Abdominoperineal res	section	94 (17.0%)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Anterior resection		413 (74.8%)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Hartmann		45 (8.15%)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Perforation		, ,	552
Mesorrecto quality:       552         Satisfactory       446 (80.8%)         Partial       63 (11.4%)         No-satisfactory       43 (7.79%)         Recidive       22 (3.99%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552	Invasion circumferential m	argin	,	552
Satisfactory       446 (80.8%)         Partial       63 (11.4%)         No-satisfactory       43 (7.79%)         Recidive       22 (3.99%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552		O	,	
Partial 63 (11.4%) No-satisfactory 43 (7.79%) Recidive 22 (3.99%) 552 Months to recidive 30.0 [5.00;60.0] 552 Metastasis 54 (9.78%) 552 Months to Metastasis 29.0 [5.00;57.2] 552 Exitus 68 (12.3%) 552			446 (80.8%)	
No-satisfactory       43 (7.79%)         Recidive       22 (3.99%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552	·		` /	
Recidive       22 (3.99%)       552         Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552	No-satisfactory		,	
Months to recidive       30.0 [5.00;60.0]       552         Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552	· ·		,	552
Metastasis       54 (9.78%)       552         Months to Metastasis       29.0 [5.00;57.2]       552         Exitus       68 (12.3%)       552	Months to recidive		,	
Months to Metastasis 29.0 [5.00;57.2] 552 Exitus 68 (12.3%) 552				
Exitus $68 (12.3\%) 552$	Months to Metastasis		` ,	
,				
	Months to exitus		31.0 [5.00;60.0]	

Table 2: According to Local Recurrence

			Crude		Multivariate	
	No event $n=530$	Event n= 22	HR	p-value	HR	p-value
Age (10y)	6.59 (1.10)	6.63 (1.05)	1.13 [0.76;1.68]	0.542	1.15 [0.74; 1.78]	0.533
Sex: Men	361 (68.1%)	16 (72.7%)	$1.18 \ [0.46; 3.02]$	0.729	$0.81 \ [0.28; \ 2.34]$	0.694
Tumor level:	,	,	, ,		, ,	
0-6cm	190 (35.8%)	14 (63.6%)	136267321 [0.00;.]	0.997	220956160.42 [0.00; Inf]	0.998
7-12cm	277 (52.3%)	8 (36.4%)	55220319 [0.00;.]	0.998	70070160.07 [0.00; Inf]	0.998
Tumor stage:	,	, ,				
0	53 (10.0%)	1 (4.55%)	0.90 [0.09; 8.61]	0.924	1.05 [0.10; 10.72]	0.969
II	162 (30.6%)	7 (31.8%)	1.88 [0.49; 7.27]	0.361	1.81 [0.44; 7.46]	0.409
III	167 (31.5%)	11 (50.0%)	3.16 [0.88;11.3]	0.077	1.79 [0.43; 7.42]	0.421
Neoadjuvant treatment	366 (69.1%)	15~(68.2%)	0.87 [0.36; 2.15]	0.769	$0.45 \ [0.16; 1.27]$	0.131
Type of resection:						
Abdominoperineal resection	88 (16.6%)	6(27.3%)	2.29 [0.86; 6.10]	0.098	0.86 [0.26; 2.86]	0.807
Hartmann	41 (7.74%)	4 (18.2%)	3.89 [1.25;12.1]	0.019	2.02 [0.53; 7.70]	0.302
Perforation	17 (3.21%)	5(22.7%)	9.55 [3.51;26.0]	< 0.001	6.52 [1.68; 25.33]	0.007
Invasion circumferential margin	37 (6.98%)	8 (36.4%)	6.61 [2.77;15.8]	< 0.001	3.13 [1.02; 9.61]	0.047
Mesorrecto quality:	, ,	` ,				
Partial	62 (11.7%)	1(4.55%)	0.31 [0.04; 2.39]	0.264	0.15 [0.02; 1.35]	0.09
No-satisfactory	36 (6.79%)	7 (31.8%)	3.61 [1.45;9.03]	0.006	1.72 [0.56; 5.30]	0.344

#### Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- $\bullet~$  Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 1: Local Recurrence




Table 3: According to Metastasis

			Crude		Multivariate		
	No event n= 498	Event n= 54	HR	p-value	HR	p-value	N
Age (10y)	6.59 (1.12)	6.56 (0.82)	1.07 [0.84;1.37]	0.583	1.22 [0.93; 1.61]	0.155	552
Sex: Men	338 (67.9%)	39 (72.2%)	1.17 [0.65;2.13]	0.602	1.34 [0.70; 2.58]	0.379	552
Tumor level:	,	,	. , ,		, ,		552
0-6cm	176 (35.3%)	28 (51.9%)	4.17 [0.99;17.5]	0.051	3.87 [0.75;19.95]	0.105	
7-12cm	261 (52.4%)	24 (44.4%)	2.48 [0.59; 10.5]	0.218	2.16 [0.43;10.91]	0.352	
Tumor stage:	, ,	, ,					552
0	54 (10.8%)	0 (0.00%)	0.00 [0.00;.]	0.995	0.00 [0.00; Inf]	0.997	
II	154 (30.9%)	15(27.8%)	6.12 [1.40;26.8]	0.016	4.78 [1.07;21.29]	0.04	
III	141 (28.3%)	37 (68.5%)	18.4 [4.43;76.4]	< 0.001	14.33 [3.38;60.80]	< 0.001	
Neoadjuvant treatment	336 (67.5%)	45~(83.3%)	2.09 [1.02;4.28]	0.044	1.54 [0.67; 3.54]	0.311	552
Type of resection:							552
Abdominoperineal resection	80 (16.1%)	$14\ (25.9\%)$	1.80 [0.97; 3.33]	0.062	0.78 [0.35; 1.72]	0.536	
Hartmann	41 (8.23%)	4 (7.41%)	1.27 [0.45; 3.57]	0.651	0.88 [0.28; 2.70]	0.818	
Perforation	18 (3.61%)	4 (7.41%)	2.76 [1.00; 7.67]	0.051	1.37 [0.43; 4.32]	0.595	552
Invasion circumferential margin	29 (5.82%)	16(29.6%)	5.45 [3.03;9.78]	< 0.001	3.34 [1.69; 6.61]	< 0.001	552
Mesorrecto quality:							552
Partial	55 (11.0%)	8 (14.8%)	0.84 [0.39; 1.79]	0.647	0.72 [0.31; 1.70]	0.457	
No-satisfactory	37 (7.43%)	6 (11.1%)	1.09 [0.46; 2.57]	0.850	0.52 [0.20; 1.34]	0.177	

## Reference categories:

- Age, a decade
- Sex, Women
- $\bullet$  Tumor level, 13-15cm
- $\bullet~$  Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 2: Metastasis




Table 4: According to Exitus

			Crude		Multivaria	ate	
	No event $n=484$	Event $n=68$	HR	p-value	HR	p-value	N
Age (10y)	6.52 (1.08)	7.04 (1.13)	1.72 [1.34;2.21]	< 0.001	1.77 [1.35;2.32]	< 0.001	552
Sex: Men	330 (68.2%)	47 (69.1%)	0.99 [0.59;1.66]	0.979	0.94 [0.55;1.63]	0.836	552
Tumor level:	330 (33.270)	11 (0011/0)	0.00 [0.00,1.00]	0.0.0	0.01 [0.00,1.00]	0.000	552
0-6cm	173 (35.7%)	31 (45.6%)	1.25 [0.55;2.84]	0.595	1.67 [0.63;4.43]	0.307	
7-12cm	255 (52.7%)	30 (44.1%)	0.85 [0.37; 1.93]	0.697	$0.76 \ [0.30; 1.91]$	0.562	
Tumor stage:	,	,	. , ,		. , ,		552
0	54 (11.2%)	0 (0.00%)	0.00 [0.00;.]	0.996	0.00 [0.00; Inf]	0.994	
II	150 (31.0%)	19(27.9%)	1.70 [0.77;3.76]	0.190	1.70 [0.75;3.83]	0.2	
III	$138 \ (28.5\%)$	40~(58.8%)	3.89 [1.89;8.03]	< 0.001	3.86 [1.79;8.33]	< 0.001	
Neoadjuvant treatment	342 (70.7%)	39 (57.4%)	0.54 [0.33; 0.87]	0.012	0.67 [0.38; 1.18]	0.162	552
Type of resection:							552
Abdominoperineal resection	$82\ (16.9\%)$	$12\ (17.6\%)$	1.43 [0.75; 2.73]	0.281	0.70 [0.32; 1.53]	0.371	
Hartmann	27 (5.58%)	18~(26.5%)	5.53 [3.15;9.70]	< 0.001	2.92 [1.54; 5.52]	0.001	
Perforation	15 (3.10%)	7 (10.3%)	3.69 [1.68;8.07]	0.001	2.08 [0.80; 5.45]	0.135	552
Invasion circumferential margin	28 (5.79%)	17 (25.0%)	3.82[2.21;6.62]	< 0.001	2.10 [1.10;4.01]	0.025	552
Mesorrecto quality:							552
Partial	$50 \ (10.3\%)$	13 (19.1%)	1.27 [0.68; 2.36]	0.450	0.82 [0.41; 1.65]	0.579	
No-satisfactory	33 (6.82%)	10 (14.7%)	1.61 [0.81;3.20]	0.176	0.68 [0.32;1.42]	0.305	

## Reference categories:

- $\bullet\,$  Age, a decade
- Sex, Women
- $\bullet$  Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- $\bullet\,$  Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 3: Exitus




Figure 4: Local Recurrence, according to Type of Resection:






Figure 5: Metastasis, according to Type of Resection:




Figure 6: Survival, according to Type of Resection:




Table 5: Incidence by outcome [95% CI]

Months	Local Recurrence	Metastasis	Exitus
12	2.23 [3.66; 0.77]	3.21 [4.87; 1.52]	4.46 [6.38; 2.5]
24	3.73 [5.64; 1.78]	7.01 [9.56; 4.38]	8.97 [11.77; 6.08]
36	4.72 [6.92; 2.48]	11.98 [15.44; 8.38]	14.23 [17.82; 10.48]
48	5.59 [8.06; 3.05]	15.44 [19.47; 11.21]	17.57 [21.6; 13.34]
60	7.37 [10.48; 4.14]	18.42 [23.03; 13.54]	20.99 [25.53; 16.18]